Syner-G BioPharma Group
Melissa Dunne has a diverse work experience in finance and accounting roles. Melissa is currently serving as the Senior Director of Finance & Accounting for Syner-G BioPharma Group, a position they have held since 2023. Prior to this, they worked as a Controller at the same company from 2021 to 2023. Before joining Syner-G BioPharma Group, Melissa was the Director of Global Finance at smartShift Technologies from 2020 to 2021. Melissa also worked as a Controller at Jenzabar from 2019 to 2020 and at Lux Research from 2016 to 2019. Earlier in their career, Melissa held roles such as Accounting Supervisor at Charles River Associates from 2015 to 2016 and Senior Accountant from 2013 to 2015. Melissa began their career at PricewaterhouseCoopers, where they worked as a Senior Assurance Associate from 2008 to 2013.
Melissa Dunne obtained a Master of Science (MS) degree in Accounting from the University of Massachusetts Amherst, where they studied from 2004 to 2009.
Syner-G BioPharma Group
Syner-G BioPharma Group provides in-depth expertise across the three key elements of Chemistry, Manufacturing, and Controls (CMC): Regulatory Services, Technical Development, and Quality/IT. We call this CMC 360™. We also provide medical writing services, with expertise in authoring a variety of regulatory documents across a wide range of therapeutic areas and in all phases of development. Our regulatory affairs services include the development and implementation of global regulatory strategic plans, regulatory agency meeting support, and electronic submissions to regulatory authorities around the world. We have the skill set and experience to guide your prime asset through any development challenges and along the ever-changing maze of regulatory filing pathways, to a position of full compliance, and high quality. Our expertise spans small molecules, peptides, oligonucleotides, biologics, monoclonal antibodies, antibody-drug conjugates, and cell and gene therapy products.